CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Sriram Ryali

Profile

Sriram Ryali

Chief Financial Officer ( Principal Financial Officer & Principal Accounting Officer ), Caribou Biosciences, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Caribou Biosciences, Inc. reported the departure of Sriram Ryali from the chief financial officer seat, with an effective date the filing does not state.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Caribou Biosciences, Inc. (CRBU)
Biological Products, (No Diagnostic Substances)
Chief Financial Officer ( Principal Financial Officer & Principal Accounting Officer )Former2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. Date not statedfiled October 6, 2026

    Caribou Biosciences, Inc. reported the departure of Sriram Ryali from the chief financial officer seat, with an effective date the filing does not state.

    The employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under […]

    [2] Filing by Caribou Biosciences, Inc., filed with the SEC on October 6, 2026. Read the filing. The record at CFO Tribune.

  2. March 5, 202610-K filed

    Sriram Ryali signed the annual report of Caribou Biosciences, Inc. on Form 10-K as Chief Financial Officer ( Principal Financial Officer & Principal Accounting Officer ), filed March 5, 2026.

    /s/ Sriram Ryali Chief Financial Officer ( Principal Financial Officer & Principal Accounting Officer )

    [1] Annual report on Form 10-K by Caribou Biosciences, Inc., filed with the SEC on March 5, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, Caribou Biosciences, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 5, 2026. sec.gov; record.
  2. Current report filed with the SEC, Caribou Biosciences, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed October 6, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Sriram Ryali wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.